# A disorder involving cannabis is gaining more attention > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/a-disorder-involving-cannabis-is-gaining-more-attention/ > **Published:** 2026-06-21T17:12:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:51:01-04:00 > **Clinical Summary:** Cannabinoid hyperemesis syndrome diagnosis and management in chronic cannabis users. Evidence-based clinical approach to CHS recognition and treatment. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyMental HealthTHCAnxietyNeurologyDosing Why This Matters [Cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome (CHS) is an emerging clinical condition that clinicians need to recognize and diagnose in patients presenting with recurrent nausea and vomiting associated with [chronic cannabis use](https://cedclinic.com/cannabis-tolerance-behavioral-models/). Understanding CHS is critical because the condition’s symptoms can mimic other gastrointestinal disorders, leading to unnecessary diagnostic testing and delayed appropriate management, which typically involves cannabis cessation. As [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) expands access and use increases, clinicians should screen for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns in patients with intractable nausea and vomiting to distinguish CHS from other conditions and provide evidence-based counseling about this under-recognized adverse effect. Clinical Summary [Cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome (CHS) is an increasingly recognized clinical condition affecting frequent, long-term cannabis users who present with cyclic severe nausea, vomiting, and abdominal pain that paradoxically improves with hot showers or baths. As [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) becomes more prevalent and potency increases due to legalization and commercial cultivation, clinicians should maintain heightened suspicion for CHS in patients with refractory nausea and vomiting, particularly those with heavy cannabis consumption histories, since the condition is often misdiagnosed and leads to unnecessary diagnostic testing and emergency department visits. The pathophysiology likely involves dysregulation of [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) in the gastrointestinal tract, though the exact mechanisms remain incompletely understood, limiting therapeutic options beyond cannabis cessation. Early recognition and counseling patients on cannabis discontinuation is critical, as CHS can significantly impair quality of life and increase healthcare utilization costs. Clinicians should screen for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns in patients presenting with cyclical gastrointestinal symptoms and educate them that continued use despite symptoms will perpetuate the condition. Patient awareness of this syndrome may improve treatment adherence and reduce unnecessary emergency care among heavy cannabis users experiencing these symptoms. Dr. Caplan’s Take “We’re seeing [cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome reported more frequently in our clinics, and while the underlying mechanism isn’t fully understood yet, the clinical pattern is real enough that we need to screen for it in patients presenting with chronic nausea and heavy cannabis use, particularly those using high-potency products.” Clinical Perspective 🏥 Cannabinoid hyperemesis syndrome (CHS) represents an emerging clinical entity that warrants increased recognition among providers managing patients with [chronic cannabis use](https://cedclinic.com/cannabis-tolerance-behavioral-models/), particularly as product potency and consumption frequency continue to escalate in legalized markets. The syndrome’s pathophysiology remains incompletely understood, with proposed mechanisms involving cannabinoid receptor overstimulation in the enteric nervous system, though individual variation in metabolism and genetic predisposition likely contribute to variable presentation and severity. Clinicians should be aware that CHS can mimic other gastrointestinal disorders, potentially leading to unnecessary investigations and delayed diagnosis, while also recognizing that cessation of cannabis remains the only reliably effective treatment despite patients’ frequent reluctance to discontinue. The expanding use of high-potency concentrates and edibles among chronic users appears to increase CHS incidence, making this a relevant concern for primary care and emergency medicine encounters. Given the prevalence of cannabis 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20A%20disorder%20involving%20cannabis%20is%20gaining%20more%20attention%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D63140)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D63140)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20A%20disorder%20involving%20cannabis%20is%20gaining%20more%20attention%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D63140)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [In the Mix: 36 More Articles — June 15, 2026](https://cedclinic.com/36-cannabis-articles-clinical-relevance-june-15-2026/) - [Unlocking the Potential of CBD for Stress Relief – Cannabis News | NUG Magazine](https://cedclinic.com/cbd-for-stress-relief-potential-cannabis-news/) - [Brain Scans Reveal Voluntary Psychedelic-Like Trance Without Drugs](https://cedclinic.com/neuroimaging-study-drug-free-altered-states/) 📰 Source: [https://www.youtube.com/watch?v=FXVFyEJXTZ4](https://www.youtube.com/watch?v=FXVFyEJXTZ4) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).